Literature DB >> 15737347

Clinicopathological characterization of monkey B virus (Cercopithecine herpesvirus 1) infection in mice.

J W Ritchey1, M E Payton, R Eberle.   

Abstract

The purpose of this study was to establish a small animal model for monkey B virus (BV) infection. Mice were inoculated intramuscularly with several BV isolates. Comparisons were based upon the doses required to produce infection (ID50), non-central nervous system (CNS) clinical disease (CS50), CNS disease (CNSD50) and lethal effect (LD50). Strains differed in respect of the dose required to produce clinical disease in BALB/c mice. C57BL/6 mice were more resistant than BALB/c mice to CNS disease. Skin lesions at the inoculation site consisted of epidermal necrosis, ulceration, serocellular crusts and underlying dermatitis. CNS lesions included marked inflammation in the ipsilateral dorsal root ganglion and lumbar spinal cord (point of viral entry). The distribution of the lumbar spinal cord lesions suggested viral entry via sensory afferent neurons, ventral motor tracts, or both. The lesions in the more cranial spinal cord segments suggested ascension to the brain via bilateral spinothalamic and spinoreticular tracts. Brain lesions included encephalitis with neuronal necrosis and white matter destruction located consistently at the base of the brainstem, the reticular system, and rostrally to the thalamus and hypothalamus. Viral antigen was detected immunohistochemically in the lesions. The results indicated an ascending encephalomyelitis syndrome similar to that produced by BV in man.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15737347     DOI: 10.1016/j.jcpa.2004.10.001

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  9 in total

1.  The complete genome sequence of herpesvirus papio 2 (Cercopithecine herpesvirus 16) shows evidence of recombination events among various progenitor herpesviruses.

Authors:  Shaun D Tyler; Alberto Severini
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Papiine herpesvirus 2 as a predictive model for drug sensitivity of Macacine herpesvirus 1 (monkey B virus).

Authors:  Lauren A Brush; Darla H Black; Kimberly A Mccormack; Lara K Maxwell; George Wright; Jerry W Ritchey; Mark E Payton; Richard Eberle
Journal:  Comp Med       Date:  2014-10       Impact factor: 0.982

3.  Genome sequence variation among isolates of monkey B virus (Macacine alphaherpesvirus 1) from captive macaques.

Authors:  R Eberle; L K Maxwell; S Nicholson; D Black; L Jones-Engel
Journal:  Virology       Date:  2017-05-07       Impact factor: 3.616

4.  Genome sequence of a pathogenic isolate of monkey B virus (species Macacine herpesvirus 1).

Authors:  Kazutaka Ohsawa; Darla Black; Makiko Ohsawa; R Eberle
Journal:  Arch Virol       Date:  2014-06-06       Impact factor: 2.574

5.  Type I IFN response to Papiine herpesvirus 2 (Herpesvirus papio 2; HVP2) determines neuropathogenicity in mice.

Authors:  K M Rogers; M Deatheridge; M A Breshears; S Chapman; D Black; J W Ritchey; M Payton; R Eberle
Journal:  Virology       Date:  2009-02-11       Impact factor: 3.616

Review 6.  Monkey B virus (Cercopithecine herpesvirus 1).

Authors:  David Elmore; Richard Eberle
Journal:  Comp Med       Date:  2008-02       Impact factor: 0.982

7.  Effective Prophylactic Therapy for Exposure to Monkey B Virus (Macacine alphaherpesvirus 1).

Authors:  Lara K Maxwell; Darla H Black; George E Wright; Melanie A Breshears; Richard Eberle
Journal:  Comp Med       Date:  2019-12-06       Impact factor: 1.565

Review 8.  Questioning the Extreme Neurovirulence of Monkey B Virus (Macacine alphaherpesvirus 1).

Authors:  R Eberle; L Jones-Engel
Journal:  Adv Virol       Date:  2018-02-13

9.  Understanding Primate Herpesviruses.

Authors:  R Eberle; L Jones-Engel
Journal:  J Emerg Dis Virol       Date:  2017-01-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.